In the past few years, AGMs have been increasingly used to hold companies accountable for their involvement in public health scandals, with some notable results. The current proxy season will revisit some of the engagement themes from previous years, in addition to exploring new areas of risk - such as the pricing of Covid-19 drugs and junk food.
Drug pricing and access strategies
Pharmaceutical companies are continuing to fall short of some shareholder expectations around drug pricing strategies and disclosure, despite years of engagement on the subject.
In 2017, a Credit Suisse report sparked widespread concern after it revealed that US pharmaceutical companies were reliant on price hikes for existing drugs to drive profit growth. According to Meg Jones-Monteiro, the health sector coordinator for shareholder body the Interfaith Center on Corporate Responsibility (ICCR), investors worried that profits would become dependent on routine pr…